EUCTR2020-005998-27-DK进行中（未招募）1 期
Interleukin-6 inhibitors and drug-drug interactions in patients with Rheumatoid Arthritis.
niversity of Southern Denmark0 个研究点目标入组 12 人开始时间: 2021年1月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Active rheumatoid arthritis
- •Age 18-75 years
- •eGFR > 30 mL/min
- •absolute neutrophil count (ANC) = 2 x 109 /L
- •Platelet count > 150 x 103 /µL (corresponding to >150 x 109 /L)
- •ALAT in the normal range or within 1.5x the upper limit of normal.
- •Use of effective contraception (only woman of childbearing potential)
- •Negative test for hepatitis and tuberculosis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •Known sensitivity to any of the medications used.
- •Active severe infections
- •Malignancy
- •Diverticulitis
- •Intake of medications which can influence the safety of the patient or the results of the study. Can include prescription medications, over-the-counter medications, herbal medicines or dietary supplements. Will be assessed by the investigators.
- •Participation in other clinical intervention trials.
- •Pregnancy or breastfeeding
研究者
相似试验
进行中（未招募）
1 期
Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failureSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code 10070267Term: SARS virus test positiveSystem Organ Class: 100000004848EUCTR2020-001275-32-DKThe Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark200
终止
1 期
Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisArthritis, RheumatoidInteractionNCT04842981University of Southern Denmark3
进行中（未招募）
不适用
Evaluation effects of treatment with an inhibitor of the receptor of a protein (interleukin-6 IL-6)involved in inflammatory process, on the clinical response and on the changes from baseline in the biomarkers in patients with rheumatoid arthritis (RA)not responding adequately to Disease-modifying antirheumatic drugs (DMARDs) and/or to a first biological agent.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-001760-30-ITOSSERVATORIO EPIDEMIOLOGICO GISEA
已完成
不适用
Effects on tocilizumab drug therapy on fat tissue proteins in rheumatoid arthritisMusculoskeletal DiseasesRheumatoid arthritisISRCTN70800019niversity of Liverpool19
招募中
2 期
The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in TabrizIRCT20200406046968N1Tabriz University of Medical Sciences10